Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors-Reference-Cited by-同舟云学术

Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors

Published:2011-11-27 Issue:12 Volume:18 Page:1331-1335
ISSN:1545-9993
Container-title:Nature Structural & Molecular Biology
language:en
Short-container-title:Nat Struct Mol Biol

Author:

Murga Matilde,Campaner Stefano,Lopez-Contreras Andres J,Toledo Luis I,Soria Rebeca,Montaña Maria F,D'Artista Luana,Schleker Thomas,Guerra Carmen,Garcia Elena,Barbacid Mariano,Hidalgo Manuel,Amati Bruno,Fernandez-Capetillo Oscar

Publisher

Springer Science and Business Media LLC

Subject

Molecular Biology,Structural Biology

Link

http://www.nature.com/articles/nsmb.2189.pdf

Reference49 articles.

1. de Bono, J.S. & Ashworth, A. Translating cancer research into targeted therapeutics. Nature 467, 543–549 (2010).

2. Bryant, H.E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).

3. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).

4. Luo, J., Solimini, N.L. & Elledge, S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823–837 (2009).

5. Raj, L. et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475, 231–234 (2011).

Cited by 340 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the ATM pathway in cancer: Opportunities, challenges and personalized therapeutic strategies;Cancer Treatment Reviews;2024-09

2. CDK12 controls transcription at damaged genes and prevents MYC-induced transcription-replication conflicts;Nature Communications;2024-08-18

3. Chemo-Phosphoproteomic Profiling with ATR Inhibitors Berzosertib and Gartisertib Uncovers New Biomarkers and DNA Damage Response Regulators;Molecular & Cellular Proteomics;2024-08

4. Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies;Journal of Medicinal Chemistry;2024-07-25

5. Hypoxia‐Responsive Prodrug of ATR Inhibitor, AZD6738, Selectively Eradicates Treatment‐Resistant Cancer Cells;Advanced Science;2024-07-08